TheEdgeResearch
Home / Stocks / NIKA

Nika Pharmaceuticals Inc. (NIKA)

OTC Healthcare Drug Manufacturers - Specialty & Generic
$0.42 ▼ -17.65%
Market Cap
$440.4M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
-2.48
52-Wk Range
0.2-0.975
CEO
Dimitar Slavchev Savov
Country
US
Currency
USD

Nika Pharmaceuticals Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Henderson, NV, US. The stock last traded at $0.42, down 17.65% on the session, giving a market capitalisation of $440.4M. On trailing twelve-month figures it carries a trailing P/E of -5653.75, a net margin of 0.0%. Its beta of -2.48 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-5653.75
Price / Sales
0.00
Price / Book
-1335.72
EV / EBITDA
-5636.83
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
Debt / equity
0.00
Current ratio
0.03
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
0
IPO date
2024-03-14
Headquarters
Henderson, NV, US
About Nika Pharmaceuticals Inc.

Nika Pharmaceuticals Inc., a pharmaceutical enterprise headquartered in Henderson, Nevada, focuses on the creation of medications to address a broad spectrum of health conditions. Its research and development efforts target serious diseases including HIV/AIDS, hepatitis B and C, rheumatoid arthritis, cancer, and diabetes. The company's product line features antiviral treatments and nutritional supplements, notably providing a specialized thymus nuclear glycoprotein for the management of HIV. Originally established in 2000, the organization was previously known as Centennial Growth Equities Inc. before adopting its current name, Nika Pharmaceuticals, Inc., in May 2022.

Comparable companies

Nika Pharmaceuticals Inc. is most often compared with the following Healthcare names:

ABTIBHCCFBHHKFCMVLFCOGZFCPHRFEDTXFFGHQFIDGXFPSIQ
More research on NIKA
NIKA technical analysis NIKA TheEdge Score Compare against peers
Open full interactive analysis & DCF →